Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more
Sinil Pharmaceutical Co. Ltd (012790) - Total Assets
Latest total assets as of September 2025: ₩169.94 Billion KRW
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) holds total assets worth ₩169.94 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sinil Pharmaceutical Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sinil Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Sinil Pharmaceutical Co. Ltd's total assets of ₩169.94 Billion consist of 46.7% current assets and 53.3% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩4.62 Billion | 0.0% |
| Accounts Receivable | ₩20.74 Billion | 12.5% |
| Inventory | ₩22.86 Billion | 13.8% |
| Property, Plant & Equipment | ₩44.79 Billion | 27.0% |
| Intangible Assets | ₩1.74 Billion | 1.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sinil Pharmaceutical Co. Ltd's current assets represent 46.7% of total assets in 2024, a decrease from 56.6% in 2014.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 4.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 27.0% of total assets.
Sinil Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Sinil Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Sinil Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Sinil Pharmaceutical Co. Ltd generates 0.54x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Sinil Pharmaceutical Co. Ltd generates $8.62 in net profit.
Sinil Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.63 | 5.00 | 5.08 |
| Quick Ratio | 3.99 | 3.51 | 3.45 |
| Cash Ratio | 0.00 | 0.45 | 0.00 |
| Working Capital | ₩68.05 Billion | ₩ 58.21 Billion | ₩ 42.39 Billion |
Sinil Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Sinil Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | ₩165.86 Billion |
| Market Capitalization | $31.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sinil Pharmaceutical Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sinil Pharmaceutical Co. Ltd's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual total assets of Sinil Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩165.86 Billion | +8.79% |
| 2023-12-31 | ₩152.46 Billion | +6.74% |
| 2022-12-31 | ₩142.83 Billion | +10.74% |
| 2021-12-31 | ₩128.97 Billion | +3.34% |
| 2020-12-31 | ₩124.81 Billion | +5.92% |
| 2019-12-31 | ₩117.84 Billion | +10.75% |
| 2018-12-31 | ₩106.40 Billion | +3.79% |
| 2017-12-31 | ₩102.52 Billion | +4.56% |
| 2016-12-31 | ₩98.05 Billion | +12.36% |
| 2015-12-31 | ₩87.26 Billion | +9.21% |
| 2014-12-31 | ₩79.91 Billion | -- |